Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7119093 | BOEHRINGER INGELHEIM | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
Feb, 2024
(10 months from now) | |
US6762180 | BOEHRINGER INGELHEIM | Substituted indolines which inhibit receptor tyrosine kinases |
Oct, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10154990 | BOEHRINGER INGELHEIM | Medicaments for the treatment or prevention of fibrotic diseases |
Dec, 2025
(2 years from now) | |
US10105323 | BOEHRINGER INGELHEIM | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Jun, 2029
(6 years from now) | |
US9907756 | BOEHRINGER INGELHEIM | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Jun, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 6, 2026 |
New Indication (I) | Mar 9, 2023 |
Market Authorisation Date: 15 October, 2014
Treatment: Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild)
Dosage: CAPSULE;ORAL
20
United States
15
European Union
6
Norway
6
Japan
5
Denmark
5
Australia
5
Slovenia
5
Argentina
5
Portugal
5
Spain
5
Korea, Republic of
5
Poland
5
China
4
South Africa
4
Mexico
4
Lithuania
4
Hungary
4
Brazil
4
Croatia
4
Cyprus
4
Peru
4
Taiwan, Province of China
4
Ukraine
4
EA
4
Canada
4
New Zealand
3
Israel
3
Uruguay
3
Malaysia
3
RS
3
Ecuador
2
Hong Kong
2
Morocco
2
Colombia
2
Chile
2
Tunisia
2
ME
1
Austria
1
Turkey
1
Egypt
1
Saudi Arabia
1
Belgium
1
Germany
1
Singapore
1
Yugoslavia
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic